공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

연쇄상구균성폐렴 : 파이프라인 리뷰

Streptococcal Pneumonia - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 362370
페이지 정보 영문 160 Pages
가격
US $ 2,000 ₩ 2,273,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,547,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,821,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


연쇄상구균성폐렴 : 파이프라인 리뷰 Streptococcal Pneumonia - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 160 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

연쇄상구균성폐렴(Streptococcal Pneumonia) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 및 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스 및 프레스 릴리스 등의 정보를 전해드립니다.

서론

연쇄상구균성폐렴 개요

치료제 개발

연쇄상구균성폐렴 : 기업에서 개발중인 치료제

연쇄상구균성폐렴 : 대학/기관에서 연구중인 치료제

연쇄상구균성폐렴 : 파이프라인 제품 개요

연쇄상구균성폐렴 : 기업에서 개발중인 제품

연쇄상구균성폐렴 : 대학/기관에서 연구중인 제품

연쇄상구균성폐렴 치료제 개발에 참여하고 있는 기업

연쇄상구균성폐렴 : 치료제 평가

약제 개요

연쇄상구균성폐렴 : 최근의 파이프라인 동향

연쇄상구균성폐렴 : 휴지중인 프로젝트

연쇄상구균성폐렴 : 개발이 중지된 제품

연쇄상구균성폐렴 : 제품 개발 마일스톤

부록

KSM 16.08.01

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape.

Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively.

Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Streptococcal Pneumonia Overview
  • Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics under Development by Companies
  • Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Pipeline Products Glance
  • Streptococcal Pneumonia - Products under Development by Companies
  • Streptococcal Pneumonia - Products under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Companies Involved in Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics Assessment
  • Drug Profiles
  • Streptococcal Pneumonia - Dormant Projects
  • Streptococcal Pneumonia - Discontinued Products
  • Streptococcal Pneumonia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Streptococcal Pneumonia, H2 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H2 2016
  • Streptococcal Pneumonia - Pipeline by Actelion Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Affinivax Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Allergan Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Arsanis Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Biken Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by ContraFect Corp, H2 2016
  • Streptococcal Pneumonia - Pipeline by Crestone Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by FluGen Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Lascco SA, H2 2016
  • Streptococcal Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Merck & Co Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Mucosis BV, H2 2016
  • Streptococcal Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Pfizer Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016
  • Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016
  • Streptococcal Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Valneva SE, H2 2016
  • Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H2 2016
  • Streptococcal Pneumonia - Pipeline by Virometix AG, H2 2016
  • Streptococcal Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016
  • Streptococcal Pneumonia - Pipeline by Wockhardt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Streptococcal Pneumonia - Dormant Projects, H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..1), H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..2), H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..3), H2 2016
  • Streptococcal Pneumonia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Streptococcal Pneumonia, H2 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q